Blair William & CO Atea Pharmaceuticals, Inc. Transaction History

Blair William & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$3.0 - $3.79 $15 - $18	-5 Reduced 0.05%	10,444 $31,000
Q2 2023 Aug 11, 2023	SELL	$3.21 - $5.06 $16 - $25	-5 Reduced 0.05%	10,449 $39,000
Q1 2023 May 12, 2023	SELL	$3.0 - $4.97 $12 - $19	-4 Reduced 0.04%	10,454 $35,000
Q4 2022 Feb 10, 2023	BUY	$4.35 - $6.17 $45,492 - $64,525	10,458 New	10,458 $50,000
Q2 2022 Aug 10, 2022	BUY	$5.33 - $8.18 $76,959 - $118,111	14,439 New	14,439 $103,000
Q1 2022 May 13, 2022	SELL	$5.5 - $9.19 $158,779 - $265,306	-28,869 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $413,750 - $2.41 Million	-53,944 Reduced 65.14%	28,869 $258,000
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $1.22 Million - $2.01 Million	57,395 Added 225.8%	82,813 $2.9 Million
Q2 2021 Aug 12, 2021	BUY	$19.22 - $59.08 $315,938 - $971,157	16,438 Added 183.05%	25,418 $546,000
Q1 2021 May 13, 2021	BUY	$41.42 - $88.44 $151,183 - $322,806	3,650 Added 68.48%	8,980 $555,000
Q4 2020 Feb 09, 2021	BUY	$26.36 - $41.78 $140,498 - $222,687	5,330 New	5,330 $223,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.